Copellor 80mg Injection

Copellor 80mg Injection contains Ixekizumab 80mg, a prescription biologic medicine and selective interleukin-17A (IL-17A) inhibitor. It is used to treat certain immune-mediated inflammatory conditions, including moderate-to-severe plaque psoriasis and psoriatic arthritis, as well as other approved inflammatory conditions depending on the patient's age and local regulatory approval.

Taltz® is the reference brand containing ixekizumab. Copellor 80mg provides the same active ingredient, ixekizumab, and may be marketed as an alternative to Taltz® depending on the applicable regulatory classification.

Product Information

Brand Name

Copellor

Generic Name

Ixekizumab

Strength

80mg

Reference Brand

Taltz®

Drug Class

Biologic / Interleukin-17A (IL-17A) Inhibitor

Indications

Plaque Psoriasis, Psoriatic Arthritis, and other approved inflammatory conditions

Dosage Form

Injection

Route

Subcutaneous Injection

Prescription

Yes

Active Ingredient

Ixekizumab

Packing

Manufacturer Dependent

Copellor 80mg and Taltz®

Taltz® contains the active ingredient ixekizumab. Copellor 80mg Injection also contains ixekizumab 80mg.

For SEO purposes, the strongest primary product name is:

Copellor 80mg Injection

Supporting terms can include:

• Ixekizumab 80mg Injection
• Ixekizumab Injection
• Taltz® alternative
• Ixekizumab 80mg
• IL-17A inhibitor
• Ixekizumab biologic

The term “generic Taltz®” or “biosimilar Taltz®” should only be used if the specific Copellor product has the corresponding regulatory classification in the target market.

Availability & Ordering

Patients searching for Copellor 80mg Injection, Ixekizumab 80mg Injection, Ixekizumab Injection, Copellor Ixekizumab, Taltz® alternative, Ixekizumab for Psoriasis, Ixekizumab for Psoriatic Arthritis, IL-17A Inhibitor, and Ixekizumab Biologic Medicine can find prescription products through licensed pharmaceutical suppliers, subject to local prescription and pharmaceutical regulations.

How it works

Ixekizumab is a humanized monoclonal antibody that selectively binds to interleukin-17A (IL-17A) and blocks its interaction with the IL-17 receptor.

IL-17A plays an important role in inflammatory and immune responses involved in conditions such as psoriasis and psoriatic arthritis. By inhibiting IL-17A activity, ixekizumab helps reduce inflammation and associated symptoms.

Copellor 80mg Injection may be prescribed for eligible patients with:

• Moderate-to-severe plaque psoriasis
• Psoriatic arthritis
• Axial spondyloarthritis, where approved
• Ankylosing spondylitis, where approved
• Other approved IL-17A-mediated inflammatory conditions depending on local regulatory authorization

The approved indications can vary by country, age group, and regulatory authority.